The UAB Department of Surgery has joined the National Institutes of Health SIREN network. SIREN will coordinate and lead high-quality multisite clinical trials to improve outcomes for patients who experience neurologic, cardiac, respiratory, hematologic and trauma emergency events.

UAB Hospital continues to be highly ranked by U.S. News and World Report, and is noted as the No. 1 hospital in Alabama.

This potential chemotherapeutic agent to treat glioblastoma — a primary brain tumor with dismal survival rates — is a novel small molecule inhibitor.

There will be more than 33,000 brain tumors diagnosed in Americans this year, according to the National Cancer Institute; but a UAB neurosurgeon says advances in treatment paint a brighter outlook than in years past.

Five faculty projects were recently funded through an AMC21 initiative giving NIH-funded investigators incentive to submit a second R01.

UAB neurosurgery’s commitment to quality care is reflected in outcomes that beat national averages in key measurements.

This rapidly fatal brain cancer has seen only two improvements in therapy in 30 years, and research findings are pointing toward a unique new human clinical trial in 2017. 

UAB investigators have won a prestigious White House BRAIN Initiative grant to study the potential benefits of new technology coupled with newly discovered biomarkers in deep brain stimulation for Parkinson’s disease.

UAB-developed technology supports a globe-spanning partnership that links pediatric neurosurgeons at UAB and Children’s of Alabama with those in Vietnam to enhance epilepsy care for Vietnamese children.

This is the second potential diagnostic application for an investigational biomarker, and discussions are underway with industry partners to develop an assay from this UAB technology.